[Diagnosis and therapy of epilepsy and myoclonus].
The pathogenesis oriented diagnoses and therapies of epilepsy and myoclonus was tended to describe, but their pathogeneses were partially elucidated. The pathogenesis of both diseases was firstly demonstrated to have genuine or hereditary factors to be discharged abnormal electrical potentials which were provoked varieties of symptoms of both epilepsy and myoclonus. The careful observation of clinical symptoms, the introduction of monitoring EEG, computed tomogram, spike voltage topography, magnetoencephalography, somatosensory evoked potential (SEP) and MRI were comparatively easily provided the diagnoses of both diseases and topographical foci of abnormal discharge. The diagnosis of myoclonus was more difficult than those of epilepsy, because the clarification of pathogenesis and definition of diagnosis was lacked. The therapies of both epilepsy and myoclonus were surgically removed the topographically abnormal discharged focus to be congenital or secondary, and their conventional discharge, monitoring the findings of EEG, and checking out the clinical symptoms and side effects of drugs. We suggest that the clear-cut description on diagnoses and therapies of both disease are required to be further investigated.
Okamoto
Y
Y
Department of Laboratory Medicine, Wakayama Medical College.
Ota
K
K
D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D002540:Cerebral Cortex / Q000503:physiopathology; D003509:Cyclohexanecarboxylic Acids; D004594:Electrophysiology; D004827:Epilepsy / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D000077206:Gabapentin; D006801:Humans; D009207:Myoclonus / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D010672:Phenytoin / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D010672:Phenytoin; D000077206:Gabapentin